Introduction
The introduction of 3-adrenoceptor blocking drugs, membrane stabilizing agents, and calcium antagonists (Vaughan-Williams, 1970; Singh and Hauswirth, 1974) has led to striking improvement in the medical management of most cardiac arrhythmias over the past 15 years. There remains a small proportion of patients with rhythm disorders which cannot be controlled with conventional therapy because of inadequate or inappropriate therapeutic effect. Toxic and side effects limit the value of some drugs, while the route or frequency of administration make others inconvenient to use. The search for new and better antiarrhythmic agents therefore continues.
Amiodarone is an effective antiarrhythmic agent neither related in structure nor similar in effects to any other drugs in current use. Although it is not freely available in the United Kingdom, enthusiastic accounts of its value have appeared from other parts of Europe (Van Schepdael and Solvay, 1970; Vastesaeger, Gillot and van der Straeten, 1971 ; Coumel and Bouvrain, 1973) and from South America (Rosenbaum et al., 1974; .
The authors now report their experience with amiodarone in 50 patients with serious arrhythmias which had proved refractory to conventional therapy. The results have been impressive, and in some cases life-saving.
prolongation of the action potential in atrial and ventricular muscle without changes in the membrane resting potential (Vaughan-Williams, 1970; Singh and Vaughan-Williams, 1970) . Amiodarone also diminishes the maximum rate of rise of the action potential and therefore slows conduction velocity (Rosenbaum et al., 1976) . In the intact heart, any delay in repolarization is manifest by prolongation of the QT interval (Facquet et al., 1970; Pritchard, Singh and Hurley, 1975; Rosenbaum et al., 1976) . Electrophysiological studies show an increase in effective refractory period. Automaticity of pacemaker cells is not usually significantly reduced (Facquet et al., 1970) although atropine-resistant bradycardia can occur on maintenance therapy (Charlier et al., 1968; Facquet et al., 1970; Pritchard et al., 1975) . Slowing of conduction may rarely potentiate pre-existing atrioventricular block (Rosenbaum et al., 1976) and unmask latent bundle branch block (Chiale et al., 1975) . Amiodarone has also been shown as having a marked anti-fibrillatory effect (Charlier et al., 1968; Singh and Vaughan-Williams, 1970) .
The appearance of microdeposits in the cornea is the most common side effect of therapy (Francois, 1968; Miller, 1969; Chiale et al., 1975) and may occur after only 14 days of treatment, perhaps as a result of lacrimal secretion (Rosenbaum et al., 1976) . The epithelial changes are reversible by stopping therapy, and they usually cause no impairment of vision. Cases of hypothyroidism (Massin et al., 1971; Barrillon and Himbert, 1971; Guinet et al., 1972) and hyperthyroidism (Jonckheer et al., 1973; Savoie et al., 1975) have occurred during treatment with amiodarone. The mechanisms for these effects are not well understood but the iodine content of amiodarone increases thyroxine production. An elevation of serum thyroxine concentration and a decrease in serum triiodothyronine concentration occur even in euthyroid patients (Pritchard et al., 1975) . Skin disorders such as photodermatitis (Rosenbaum et al., 1976) and melanodermatitis (Geerts, 1971 ) are thought to be related to deposition of crystals. Erythema nodosum (Rosenbaum et al., 1976) and toxic erythematous drug reactions occur rarely. Other reported side effects include tremor of Parkinsonian type (Lhuillier and Gouin, 1972) and one case of peripheral neuropathy (Lustman and Monseu, 1974) . Unlike most other antiarrhythmics with a therapeutic range close to toxicity, it has a wide margin of safety (Rosenbaum et al., 1976) . Experimentally the LD50 for amiodarone is ten times the therapeutic dose when given i.v. (Charlier et al., 1962) . Acute 
Results
The results for the groups described above are shown in Tables 1, 2 and 3. Rosenbaum's system (Rosenbaum et al., 1976) (Hobbs and Calnan, 1958) , chlorpromazine toxicity (Johnson and Buffaloe, 1966) and the recently described keratopathy in some patients treated with clofazimine (a phenazine derivative) (Walinder, Gip and Stempa, 1976 (Charlier et al., 1968; Barzin and Fr6son, 1969; Singh et al., 1976) . Thirdly, serious toxicity is rare and overdosage by the oral route is not hazardous (Rosenbaum et al., 1976) . Finally it has a sustained action: doses once daily or on alternate days may maintain effective tissue levels of the drug. Therapeutic activity can continue for weeks after treatment has stopped (Broekhuysen, Laruel and Sion, 1969; Rosenbaum et al., 1976) .
The cumulative action depending on slowly increasing tissue levels has one disadvantage -effects cannot be obtained rapidly even with intravenous use. It has been found that 2-7 days are required for clinical effects, and these probably increase over several weeks. Amiodarone is therefore of little value in emergencies although it may be given appropriately with a thought to subsequent management if the patient can be sustained over the first critical days. Coumel and Bouvrain (1973) showed that amiodarone was effective for a variety of atrial and ventricular arrhythmias, including reciprocating tachycardias and refractory atrial fibrillation complicating the WPW syndrome. Their observation led to the present authors' first use of amiodarone later the same year for a patient with WPW syndrome who was unresponsive to other therapy (Chamberlain and Clark, 1977) . Rosenbaum et al. (1974) amply confirmed the near-specific effect in pre-excitation syndromes and have reported total suppression of arrhythmias in all 27 patients treated with the drug. Other groups have had similar experiences (Wellens et al., 1976) .
Most cases of supraventricular tachycardia depend upon reciprocating wave frohts within dual II II II II II II II II II II II II II II pathways involving both atria and ventricles (Bigger and Goldreyer, 1970) or sometimes only atria and the atrio-ventricular node (Kistin, 1965) . Dual pathways can exist within the nodal-His system but in an unknown proportion of patients the retrograde pathway is anomalous, lying outside the normal conducting tissue. If pre-excitation does not occur during antegrade conduction, the mechanism is not apparent from conventional electrocardiograms (Krikler, 1974 
